Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02722525 · ClinicalTrials.gov registry record · NA
Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer
A NA study of Prostate Carcinoma and Cardiovascular Injury, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02722525: Active NA study of Prostate Carcinoma and Cardiovascular Injury, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02722525 is a NA study of Prostate Carcinoma and Cardiovascular Injury that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 23 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02722525, a NA study of Prostate Carcinoma and Cardiovascular Injury, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Learning about the impact of anti-androgen treatment has on cardiac function in patients with prostate cancer may help plan treatment and help patients live more comfortably. This pilot clinical trial will utilize cardiac magnetic resonance imaging (MRI) before a patient starts hormone therapy and after 4 to 7 months of hormone therapy. The objective is to measure the impact of hormone therapy (anti-androgen treatment) on cardiac function in patients with prostate cancer.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- BEHAVIORAL Exercise Intervention
- PROCEDURE Spectroscopy
- PROCEDURE Perfusion Magnetic Resonance Imaging
Study Locations (1)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-12 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT02722525 still lists
NCT02722525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02722525 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02722525 about?
NCT02722525 is a clinical study titled "Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer". Learning about the impact of anti-androgen treatment has on cardiac function in patients with prostate cancer may help plan treatment and help patients live more comfortably. This pilot clinical trial will utilize cardiac magnetic resonance imaging (MRI) before a patient starts hormone therapy and a...
What is the current status of trial NCT02722525?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 23 participants. The study started on 2014-12. Estimated completion is 2026-12-31.
What conditions does trial NCT02722525 study?
This clinical trial studies the following conditions: Prostate Carcinoma, Cardiovascular Injury.
What interventions are being tested in trial NCT02722525?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Exercise Intervention (BEHAVIORAL), Spectroscopy (PROCEDURE), Perfusion Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02722525?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02722525 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02722525's enrollment target sits among peer trials
23 54th of 59 higher than 6 of 59 other Prostate Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
RECRUITING · NA
-
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
RECRUITING · NA
-
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
RECRUITING · NA
-
[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer
RECRUITING · NA
-
Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia